Compare Globus Medical Inc. Class A Common Stock (GMED) vs KLA Corp. (KLAC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs KLA Corp. — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while KLA Corp. trades at $174.91 (market cap $240.12B). The key difference: KLA Corp. is far larger — about 23.4× Globus Medical Inc. Class A Common Stock's market cap, and KLA Corp. pays a 0.5% dividend while Globus Medical Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and KLA Corp. for 60 Days on average.
| GMED | KLAC | |
|---|---|---|
Market Cap | $10.25B | $240.12B |
Volume | 1,108,124 | 10,439,404 |
Sector | Health | Technology |
52-Week High | $96.82 | $301.71 |
52-Week Low | $58.33 | $108.70 |
Typical Hold Time | 0 Days | 60 Days |
Enterprise Value | $9.76B | $241.37B |
Dividend Yield | — | 0.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
KLA Corporation (KLAC) trades at $178.81, down 5.95% on the day, amid a broader tech selloff. The stock maintains a bullish technical signal, with strong fundamentals including a 35.57% net income margin and consistent earnings beats. Revenue reached $12.16B in 2025, with a robust backlog of $12.57B driven by AI demand, positioning the company for growth in semiconductor equipment.
The outlook remains positive with a consensus price target of $223.88, implying significant upside. Risks include competitive pressures from Applied Materials and ASML, and sensitivity to semiconductor capex cycles. Analyst sentiment is strongly bullish, with 28 buy ratings, supporting a favorable long-term investment case despite near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About KLA Corp.
KLA designs and manufactures yield-management and process-monitoring diagnostic and control systems for the semiconductor manufacturing industry. The systems are used to analyze the manufacturing process at various steps in a semiconductor's development. The firm's laser-scanning products are used for wafer qualification, process monitoring, and equipment monitoring. KLA also provides inspection tools and systems for optical metrology and e-beam metrology.
Read more on KLAC →
